Clofarabine, cytarabine, and mitoxantrone in refractory/relapsed acute myeloid leukemia: High response rates and effective bridge to allogeneic hematopoietic stem cell transplantation

Clofarabine is active in refractory/relapsed acute myeloid leukemia (AML). In this phase 2 study, we treated 18‐ to 65‐year‐old AML patients refractory to first‐line 3 + 7 daunorubicin/cytarabine induction or relapsing after 3 + 7 induction and high‐dose cytarabine consolidation, with clofarabine (3...

Descripción completa

Detalles Bibliográficos
Autores principales: Gill, Harinder, Yim, Rita, Pang, Herbert H., Lee, Paul, Chan, Thomas S. Y., Hwang, Yu‐Yan, Leung, Garret M. K., Ip, Ho‐Wan, Leung, Rock Y. Y., Yip, Sze‐Fai, Kho, Bonnie, Lee, Harold K. K., Mak, Vivien, Chan, Chi‐Chung, Lau, June S. M., Lau, Chi‐Kuen, Lin, Shek‐Yin, Wong, Raymond S. M., Li, Wa, Ma, Edmond S. K., Li, Jun, Panagiotou, Gianni, Sim, Joycelyn P. Y., Lie, Albert K. W., Kwong, Yok‐Lam
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7221314/
https://www.ncbi.nlm.nih.gov/pubmed/32187883
http://dx.doi.org/10.1002/cam4.2865

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7221314/
https://www.ncbi.nlm.nih.gov/pubmed/32187883
http://dx.doi.org/10.1002/cam4.2865

Ejemplares similares